Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LUZ Capital Partners is an investment firm founded in 2024 that specializes in acquiring and operating private companies across various sectors. The firm emphasizes preserving the legacy and culture of acquired businesses while driving sustainable growth through operational excellence. While healthcare is among their focus industries, they are not exclusively dedicated to life sciences or biotech. The team is led by Danilo Boavista and Rafael Pacheco, who bring backgrounds in entrepreneurship, management consulting—including experience with McKinsey & Company’s life sciences practice—and financial operations.
The firm has raised $920K from professional investors including KMMT Capital, Health Catalyst Capital Management, UPMC Enterprises, Applied Equity, Generational Transfer Entrepreneurs (GTE), Hadley Family Capital, Kamylon Partners, Kinderhook Partners, Martell Capital Partners, Northspring Partners, Operand Group, Spectra Investments and Vonzeo Capital. Their approach involves hands-on management post-acquisition to ensure seamless transitions for acquired companies.
They do not develop drugs or medical products themselves but may acquire companies within the healthcare sector as part of their broader investment strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LUZ Capital Partners.